KRAS and cancer: One is that the pro-oncogenic role we have uncovered for KRAS in nuclear protein export provides at least a partial explanation for the limited clinical success when inhibitors of canonical RAS signaling, such as MEKi and PI3Ki, have been used in cancer treatment30,31.